1
|
Molecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma. Invest Radiol 2014; 48:413-21. [PMID: 23262791 DOI: 10.1097/rli.0b013e31827a4a3f] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVES The objective of this study was to quantitatively compare tumor imaging by magnetic resonance imaging (MRI) and molecular bioluminescence imaging (BLI) and test the feasibility of monitoring the effect of MRI-guided laser ablation on tumor viability by 2-dimensional BLI and 3-dimensional diffuse luminescence tomography (3D DLIT) in an orthotopic rat model of hepatocellular carcinoma. MATERIALS AND METHODS This study was approved by the animal care committee. Rats underwent injection of N1S1 cells stably transfected with an empty vector (n = 3) or a heat shock element luciferase reporter (HSE-luc; n = 4) into the liver. All rats underwent MRI to assess tumor establishment and volume and 2-dimensional BLI to assess tumor luminescence at day 7 with subsequent MRI and 2D BLI and 3D DLIT in select animals at days 14 and 21. Magnetic resonance imaging-guided laser ablation of the tumor was performed with preablation and postablation 2D BLI and/or 3D DLIT (n = 2). The tumors underwent histopathologic analysis to assess tumor viability. RESULTS The MRI scans demonstrated hyperintense T2-weighted lesions at 3 of 3 and 4 of 4 sites in the empty vector and HSE-luc rats, respectively. Two-dimensional BLI quantitation demonstrated 23.0-fold higher radiance in the HSE-luc group compared with the empty vector group at day 7 (P < 0.01) and a significant correlation with tumor volume by MRI (r = 0.86; P < 0.03). Tumor dimensions by 3D DLIT and MRI demonstrated good agreement. Three-dimensional DLIT quantitation demonstrated better agreement with the percentage of nonviable tumor by histopathology than did 2D BLI quantitation after the MRI-guided laser ablation. CONCLUSIONS Bioluminescence imaging is feasible as a noninvasive, quantitative tool for monitoring tumor growth and therapeutic response to thermal ablation in a rat model of hepatocellular carcinoma.
Collapse
|
2
|
Sugiyama T, Yoneda M, Kuraishi T, Hattori S, Inoue Y, Sato H, Kai C. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Gene Ther 2012; 20:338-47. [PMID: 22717740 DOI: 10.1038/gt.2012.44] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Oncolytic viruses hold much promise as novel therapeutic agents that can be combined with conventional therapeutic modalities. Measles virus (MV) is known to enter cells using the signaling lymphocyte activation molecule (SLAM), which is expressed on cells of the immune system. Although human breast cancer cell lines do not express SLAM, we found that a wild-type MV (HL strain) efficiently infected various breast cancer cell lines, causing cell death. Based on this finding, we used reverse genetics to generate a recombinant MV selectively unable to use SLAM (rMV-SLAMblind). The rMV-SLAMblind lacked infectivity for SLAM-positive lymphoid cells, while retaining oncolytic activity against breast cancer cells. We showed that, unlike the MV vaccine strains, rMV-SLAMblind used PVRL4 (polio virus receptor-related 4) as a receptor to infect breast cancer cells and not the ubiquitously expressed CD46. Consistent with this, rMV-SLAMblind infected CD46-positive primary normal human cells at a much-reduced level, whereas a vaccine strain of the Edmonston lineage (rMV-Edmonston) efficiently infected and killed them. The rMV-SLAMblind showed antitumor activity against human breast cancer xenografts in immunodeficient mice. The oncolytic activity of rMV-SLAMblind was significantly greater than that of rMV-Edmonston. To assess the in vivo safety, three monkeys seronegative for MV were inoculated with rMV-SLAMblind, and no clinical symptoms were documented. On the basis of these results, rMV-SLAMblind could be a promising candidate as a novel oncolytic virus for breast cancer treatment.
Collapse
Affiliation(s)
- T Sugiyama
- Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
3
|
Inoue Y, Masutani Y, Kiryu S, Haishi T, Yoshikawa K, Watanabe M, Shimada M, Ohtomo K. Integrated Lymphography using Fluorescence Imaging and Magnetic Resonance Imaging in Intact Mice. Mol Imaging 2011; 10:317-26. [DOI: 10.2310/7290.2010.00049] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Yusuke Inoue
- From the Department of Radiology, Institute of Medical Science and Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Image Computing and Analysis laboratory, Department of Radiology, University of Tokyo Hospital, Tokyo, Japan; MRTechnology Inc., Tsukuba, Japan; amd Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University, Tokyo, Japan
| | - Yoshitaka Masutani
- From the Department of Radiology, Institute of Medical Science and Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Image Computing and Analysis laboratory, Department of Radiology, University of Tokyo Hospital, Tokyo, Japan; MRTechnology Inc., Tsukuba, Japan; amd Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University, Tokyo, Japan
| | - Shigeru Kiryu
- From the Department of Radiology, Institute of Medical Science and Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Image Computing and Analysis laboratory, Department of Radiology, University of Tokyo Hospital, Tokyo, Japan; MRTechnology Inc., Tsukuba, Japan; amd Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University, Tokyo, Japan
| | - Tomoyuki Haishi
- From the Department of Radiology, Institute of Medical Science and Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Image Computing and Analysis laboratory, Department of Radiology, University of Tokyo Hospital, Tokyo, Japan; MRTechnology Inc., Tsukuba, Japan; amd Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University, Tokyo, Japan
| | - Kohki Yoshikawa
- From the Department of Radiology, Institute of Medical Science and Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Image Computing and Analysis laboratory, Department of Radiology, University of Tokyo Hospital, Tokyo, Japan; MRTechnology Inc., Tsukuba, Japan; amd Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University, Tokyo, Japan
| | - Makoto Watanabe
- From the Department of Radiology, Institute of Medical Science and Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Image Computing and Analysis laboratory, Department of Radiology, University of Tokyo Hospital, Tokyo, Japan; MRTechnology Inc., Tsukuba, Japan; amd Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University, Tokyo, Japan
| | - Morio Shimada
- From the Department of Radiology, Institute of Medical Science and Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Image Computing and Analysis laboratory, Department of Radiology, University of Tokyo Hospital, Tokyo, Japan; MRTechnology Inc., Tsukuba, Japan; amd Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University, Tokyo, Japan
| | - Kuni Ohtomo
- From the Department of Radiology, Institute of Medical Science and Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Image Computing and Analysis laboratory, Department of Radiology, University of Tokyo Hospital, Tokyo, Japan; MRTechnology Inc., Tsukuba, Japan; amd Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University, Tokyo, Japan
| |
Collapse
|